Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Better Health, an iPhone App Away

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

An Apple a day might not keep the doctor away, but the company's AppStore carries several solutions for tracking health care on the go -- and pharmaceutical companies continue to line up as backers.

VIVUS  (NASDAQ: VVUS  ) has a newly released weight loss app that can be used by anyone, but the company's obviously aiming at potential customers for its obesity drug Qsymia. The Q and Me app allows for the tracking of exercise and diet, while providing access to recipes and metrics readouts.

The VIVUS app has a lot of competition from long-standing nutrition sites like MyFitnessPal. But Q and Me becomes the latest in a growing trend of mobile solutions backed by pharmaceutical companies.

iBGStar Diabetes Manager (Sanofi)
Sanofi  (NYSE: SNY  ) supplements its multibillion-dollar insulin Lantus with a smartphone-enabled blood glucose monitor. The small iBGStar monitor can function on its own or connect to an Apple iPhone or iPad for tracking.

The accompanying app allows users to track meals, exercise, and glucose levels -- all important factors in diabetes management. Blood sugar tracked over time can provide metrics showing the cause and effect of certain activities, such as jogging or eating a doughnut.

iChemoDiary (Merck)
Merck's  (NYSE: MRK  ) iChemoDiary app  helps patients track chemotherapy treatments and record notes. The app also provides information about different drugs and their potential side effects. Patients can easily share the information with health care providers to identify any potential problems with the current regimen.

Cancer treatments tend toward intense personalization, both in the treatments used and the side effects suffered. This app could vastly streamline the process for both patient and doctor.

The free app is available through Apple's iTunes and for desktop use. It's branded through Merck's medication Emend, which treats chemo-related nausea.

Psoriasis App (Johnson & Johnson)
Johnson & Johnson  (NYSE: JNJ  ) subsidiary Janssen backs a Psoriasis App that includes functions for both health care providers and patients. The company's psoriasis drug Stelara reached blockbuster status last year.

The app includes a Psoriasis Area & Severity Index, which provides an interactive anatomical graph of where on the body a patient's psoriasis is affecting and to what extent. Patients can also answer and share a questionnaire to help doctors determine the best treatment.

Download the app through Apple's iTunes or you can use the online version.

Foolish final thoughts
The specialized apps from Johnson & Johnson and Merck serve as better promotions for their drugs than the easily replicated general topics like VIVUS' weight loss app. Sanofi's program will actually drive revenues, since there's a physical device required.

While it's unlikely these apps will move the needle too much in the near term, our health care system desperately needs to improve patient adherence when it comes to prescription drugs. Given this need, and the pervasiveness of smartphones, I expect more and more pharmaceutical companies and insurers to jump on this bandwagon in the future.

If smartphone apps can be used to improve patient adherence, it could help us stop what Warren Buffett has referred to as "the tapeworm that's eating at American competitiveness." In a special free report titled "What's Really Eating At America's Competitiveness," you'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2310550, ~/Articles/ArticleHandler.aspx, 9/26/2016 3:07:42 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,104.93 -156.52 -0.86%
S&P 500 2,147.59 -17.10 -0.79%
NASD 5,261.99 -43.75 -0.82%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 2:52 PM
JNJ $117.71 Down -1.10 -0.93%
Johnson and Johnso… CAPS Rating: *****
MRK $61.98 Down -0.99 -1.56%
Merck and Co. CAPS Rating: ****
SNY $38.03 Down -0.32 -0.83%
Sanofi CAPS Rating: *****
VVUS $1.22 Up +0.09 +8.05%
VIVUS CAPS Rating: **